WO2003068164A3 - Dosing regimen for gemcitabine hcv therapy - Google Patents
Dosing regimen for gemcitabine hcv therapy Download PDFInfo
- Publication number
- WO2003068164A3 WO2003068164A3 PCT/US2003/004481 US0304481W WO03068164A3 WO 2003068164 A3 WO2003068164 A3 WO 2003068164A3 US 0304481 W US0304481 W US 0304481W WO 03068164 A3 WO03068164 A3 WO 03068164A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapy
- days
- gemcitabine
- viral
- dosing regimen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2004-7012662A KR20040091052A (en) | 2002-02-14 | 2003-02-14 | Dosing regimen for gemcitabine HCV therapy |
EP03713459A EP1482943A2 (en) | 2002-02-14 | 2003-02-14 | Dosing regimen for gemcitabine hcv therapy |
CA002476282A CA2476282A1 (en) | 2002-02-14 | 2003-02-14 | Dosing regimen for gemcitabine hcv therapy |
AU2003217414A AU2003217414A1 (en) | 2002-02-14 | 2003-02-14 | Dosing regimen for gemcitabine hcv therapy |
JP2003567349A JP2006505490A (en) | 2002-02-14 | 2003-02-14 | Dosage plan for gemcitabine HCV treatment |
MXPA04007878A MXPA04007878A (en) | 2002-02-14 | 2003-02-14 | Dosing regimen for gemcitabine hcv therapy. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35741102P | 2002-02-14 | 2002-02-14 | |
US60/357,411 | 2002-02-14 | ||
US35814002P | 2002-02-20 | 2002-02-20 | |
US60/358,140 | 2002-02-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003068164A2 WO2003068164A2 (en) | 2003-08-21 |
WO2003068164A3 true WO2003068164A3 (en) | 2004-03-11 |
Family
ID=27737594
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/004379 WO2003068162A2 (en) | 2002-02-14 | 2003-02-13 | Modified fluorinated nucleoside analogues |
PCT/US2003/004481 WO2003068164A2 (en) | 2002-02-14 | 2003-02-14 | Dosing regimen for gemcitabine hcv therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/004379 WO2003068162A2 (en) | 2002-02-14 | 2003-02-13 | Modified fluorinated nucleoside analogues |
Country Status (12)
Country | Link |
---|---|
US (2) | US20040002476A1 (en) |
EP (2) | EP1480982A4 (en) |
JP (2) | JP2005522443A (en) |
KR (2) | KR20040094692A (en) |
CN (2) | CN1646534A (en) |
AU (2) | AU2003217402A1 (en) |
BR (1) | BR0307712A (en) |
CA (2) | CA2476279A1 (en) |
MX (2) | MXPA04007876A (en) |
NZ (1) | NZ534811A (en) |
WO (2) | WO2003068162A2 (en) |
ZA (1) | ZA200406858B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9186369B2 (en) | 2003-07-25 | 2015-11-17 | Idenix Pharmaceuticals, Llc | Purine nucleoside analogues for treating flaviviridae including hepatitis C |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2319732T3 (en) | 2000-04-13 | 2009-05-12 | Pharmasset, Inc. | DERIVATIVES OF NUCLEOSIDE 3'- OR 2'-HYDROXIMETHYL REPLACED FOR THE TREATMENT OF VIRAL INFECTIONS. |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
WO2001092282A2 (en) * | 2000-05-26 | 2001-12-06 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
WO2003026589A2 (en) * | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
US20040197321A1 (en) * | 2002-03-19 | 2004-10-07 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
US20030180279A1 (en) * | 2002-03-19 | 2003-09-25 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
KR20050035194A (en) * | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
CN101172993A (en) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
BR0313164A (en) | 2002-08-01 | 2007-07-17 | Pharmasset Inc | compounds with the non-bicyclic system [4.2.1] for the treatment of flaviviridae infections |
US20040067877A1 (en) | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
KR20050088079A (en) * | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-branched nucleosides and flaviviridae mutation |
CA2509687C (en) * | 2002-12-12 | 2012-08-14 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
WO2004058792A1 (en) * | 2002-12-23 | 2004-07-15 | Idenix (Cayman) Limited | Process for the production of 3'-nucleoside prodrugs |
WO2004084796A2 (en) * | 2003-03-28 | 2004-10-07 | Pharmasset Ltd. | Compounds for the treatment of flaviviridae infections |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
BRPI0512360A (en) * | 2004-06-23 | 2008-03-11 | Idenix Cayman Ltd | 5-aza-7-deazapurine derivatives for the treatment of flaviviridae |
US7524831B2 (en) | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
KR101298631B1 (en) | 2005-06-07 | 2013-08-30 | 예일 유니버시티 | methods of treating cancer and other conditions or disease statesusing LFMAU and LDT |
US7951788B2 (en) * | 2005-12-02 | 2011-05-31 | Yale University | Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs |
WO2007075876A2 (en) * | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
CA2849420C (en) * | 2007-09-17 | 2016-07-12 | Abbvie Bahamas Ltd. | Anti-infective pyrimidines and uses thereof |
JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
US20100021505A1 (en) * | 2008-07-28 | 2010-01-28 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
WO2010027005A1 (en) | 2008-09-05 | 2010-03-11 | 壽製薬株式会社 | Substituted amine derivative and medicinal composition comprising same as the active ingredient |
UY33445A (en) * | 2010-06-10 | 2012-01-31 | Gilead Sciences Inc | A DOSAGE SCHEME, METHODS TO TREAT HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITION, COMPOSITE, ANTI-HCV COMPOUNDS AND KIT |
CN104884462A (en) * | 2012-10-29 | 2015-09-02 | 共晶制药股份有限公司 | Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer |
HUE044605T2 (en) | 2012-11-16 | 2019-11-28 | Univ College Cardiff Consultants Ltd | Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate |
ES2623287T3 (en) | 2013-04-12 | 2017-07-10 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for HCV treatment |
CN108135920A (en) | 2015-10-05 | 2018-06-08 | 努卡那有限公司 | Combination treatment |
WO2018200859A1 (en) * | 2017-04-26 | 2018-11-01 | Kalman Thomas I | Multitargeted nucleoside derivatives |
JP2020125245A (en) * | 2019-02-01 | 2020-08-20 | ダイキン工業株式会社 | Anti-hepatitis C virus agent |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000021565A1 (en) * | 1998-10-13 | 2000-04-20 | Du Pont Pharmaceuticals Company | Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
EP0184365B1 (en) * | 1984-12-04 | 1993-08-04 | Eli Lilly And Company | Improvements in the treatment of tumors in mammals |
GB8719367D0 (en) * | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
HU204843B (en) * | 1988-09-27 | 1992-02-28 | Merrell Dow Pharma | Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same |
ZA898567B (en) * | 1988-11-15 | 1990-08-29 | Merrell Dow Pharma | Novel 2'-halomethylidene,2'-ethenylidene and 2'-ethynyl cytidine,uridine and guanosine derivatives |
US5616702A (en) * | 1988-11-15 | 1997-04-01 | Merrell Pharmaceuticals Inc. | 2-'-ethenylidene cytidine, uridine and guanosine derivatives |
US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
TW224053B (en) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
DK0664708T3 (en) * | 1992-04-10 | 1998-11-02 | Merrell Pharma Inc | Method of treating cancer by combination therapy with 2'-halomethylidene derivatives and an S-phase or M-phase spec |
CA2133961C (en) * | 1992-05-12 | 1998-03-31 | James R. Mccarthy | A process for the preparation of ribonucleotide reductase inhibitors |
YU43193A (en) * | 1992-06-22 | 1997-01-08 | Eli Lilly And Company | 2'-DEOXY-2 ', 2'-DIFLUORO (4-SUBSTITUTED) PYRIMIDINE NUCLEOSIDS OF ANTIVIRUS AND ANTICANCEROGENIC ACTIVITY AND INTERMEDIATES |
WO1994019012A2 (en) * | 1993-02-24 | 1994-09-01 | Wang Jui H | Compositions and methods of application of reactive antiviral polymers |
CA2167537A1 (en) * | 1993-07-19 | 1995-02-02 | Tsuneo Ozeki | Hepatitis c virus proliferation inhibitor |
DE4432623A1 (en) * | 1994-09-14 | 1996-03-21 | Huels Chemische Werke Ag | Process for bleaching aqueous surfactant solutions |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
GB9601680D0 (en) * | 1996-01-27 | 1996-03-27 | Pfizer Ltd | Therapeutic agents |
US5980884A (en) * | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
US5830905A (en) * | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5891874A (en) * | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
US5922757A (en) * | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
EP1009732B1 (en) * | 1997-06-30 | 2003-05-21 | MERZ + CO. GmbH & Co. | 1-amino-alkylcyclohexane nmda receptor antagonists |
EP1058686B1 (en) * | 1998-02-25 | 2006-11-02 | Emory University | 2'-fluoronucleosides |
GB9806815D0 (en) * | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
CZ20022825A3 (en) * | 2000-02-18 | 2003-05-14 | Shire Biochem Inc. | Nucleoside analogs intended for use when treating or prophylaxis infections induced by flavivirus |
JP2004505114A (en) * | 2000-08-02 | 2004-02-19 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Improved antiviral and antitumor chemotherapy by administration of erythropoietin |
US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
CA2442979C (en) * | 2001-03-30 | 2010-02-16 | Triangle Pharmaceuticals, Inc. | Process for the preparation of 2'-halo-.beta.-l-arabinofuranosyl nucleosides |
-
2003
- 2003-02-13 WO PCT/US2003/004379 patent/WO2003068162A2/en active Application Filing
- 2003-02-13 US US10/366,144 patent/US20040002476A1/en not_active Abandoned
- 2003-02-13 CN CNA038083728A patent/CN1646534A/en active Pending
- 2003-02-13 KR KR10-2004-7012661A patent/KR20040094692A/en not_active Application Discontinuation
- 2003-02-13 EP EP03713447A patent/EP1480982A4/en not_active Withdrawn
- 2003-02-13 JP JP2003567347A patent/JP2005522443A/en not_active Withdrawn
- 2003-02-13 BR BR0307712-8A patent/BR0307712A/en not_active IP Right Cessation
- 2003-02-13 MX MXPA04007876A patent/MXPA04007876A/en not_active Application Discontinuation
- 2003-02-13 CA CA002476279A patent/CA2476279A1/en not_active Abandoned
- 2003-02-13 AU AU2003217402A patent/AU2003217402A1/en not_active Abandoned
- 2003-02-13 NZ NZ534811A patent/NZ534811A/en not_active IP Right Cessation
- 2003-02-14 AU AU2003217414A patent/AU2003217414A1/en not_active Abandoned
- 2003-02-14 JP JP2003567349A patent/JP2006505490A/en not_active Withdrawn
- 2003-02-14 WO PCT/US2003/004481 patent/WO2003068164A2/en active Search and Examination
- 2003-02-14 EP EP03713459A patent/EP1482943A2/en not_active Withdrawn
- 2003-02-14 MX MXPA04007878A patent/MXPA04007878A/en unknown
- 2003-02-14 US US10/367,388 patent/US20030225029A1/en not_active Abandoned
- 2003-02-14 KR KR10-2004-7012662A patent/KR20040091052A/en not_active Application Discontinuation
- 2003-02-14 CN CNA03808385XA patent/CN1646129A/en active Pending
- 2003-02-14 CA CA002476282A patent/CA2476282A1/en not_active Abandoned
-
2004
- 2004-08-27 ZA ZA2004/06858A patent/ZA200406858B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000021565A1 (en) * | 1998-10-13 | 2000-04-20 | Du Pont Pharmaceuticals Company | Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9186369B2 (en) | 2003-07-25 | 2015-11-17 | Idenix Pharmaceuticals, Llc | Purine nucleoside analogues for treating flaviviridae including hepatitis C |
Also Published As
Publication number | Publication date |
---|---|
WO2003068164A2 (en) | 2003-08-21 |
AU2003217414A1 (en) | 2003-09-04 |
ZA200406858B (en) | 2005-09-28 |
JP2005522443A (en) | 2005-07-28 |
EP1480982A4 (en) | 2007-08-01 |
JP2006505490A (en) | 2006-02-16 |
AU2003217414A8 (en) | 2003-09-04 |
AU2003217402A1 (en) | 2003-09-04 |
WO2003068162A3 (en) | 2004-03-11 |
KR20040094692A (en) | 2004-11-10 |
KR20040091052A (en) | 2004-10-27 |
US20030225029A1 (en) | 2003-12-04 |
EP1480982A2 (en) | 2004-12-01 |
US20040002476A1 (en) | 2004-01-01 |
MXPA04007876A (en) | 2005-06-20 |
CN1646129A (en) | 2005-07-27 |
EP1482943A2 (en) | 2004-12-08 |
MXPA04007878A (en) | 2005-06-20 |
WO2003068162A2 (en) | 2003-08-21 |
CN1646534A (en) | 2005-07-27 |
NZ534811A (en) | 2007-07-27 |
BR0307712A (en) | 2005-05-24 |
CA2476279A1 (en) | 2003-08-21 |
CA2476282A1 (en) | 2003-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003068164A3 (en) | Dosing regimen for gemcitabine hcv therapy | |
AR048431A1 (en) | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS | |
WO2005020884A3 (en) | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses | |
TW200500375A (en) | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae | |
NO20060981L (en) | Pyridazine derivatives and their use as therapeutic agents | |
TW200505881A (en) | Tri(cyclo) substituted amide compounds | |
MXPA05013637A (en) | Gsk-3 inhibitors and uses thereof. | |
RU2003131876A (en) | COMPOSITIONS OF N-ACETYLCYSTEINE AND METHODS OF TREATMENT AND PREVENTION OF TOXICITY OF MEDICINES | |
WO2008054454A3 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
TW200510391A (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
WO2006130553A3 (en) | Hcv protease inhibitors | |
NO20062504L (en) | Compositions and dosage forms for improved absorption | |
HK1086186A1 (en) | Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain | |
NO20065904L (en) | Therapeutic compounds | |
WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
WO2004032909A3 (en) | Stabilized pharmaceutical composition containing basic excipients | |
WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
TNSN04203A1 (en) | Benzoxazinone-derived compounds, their preparation and use as medicaments | |
GB0222514D0 (en) | Organic compounds | |
NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
HK1077215A1 (en) | A pharmaceutical composition for treatment of acute myocardial infarction | |
TW200501940A (en) | Virus therapeutic drug | |
RU2006113366A (en) | THERAPEUTIC TREATMENT | |
PE20040706A1 (en) | SPECIFIC DERIVATIVE OF AMINE CYCLIC AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS INVOLVED IN THE PREVENTION OF HEART FAILURE | |
ATE545423T1 (en) | AGENTS FOR THE TREATMENT OF LUNG CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/007878 Country of ref document: MX Ref document number: 2003567349 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047012662 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2476282 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003713459 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003808385X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003713459 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003713459 Country of ref document: EP |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0307709 Country of ref document: BR Free format text: PEDIDO RETIRADO FACE A IMPOSSIBILIDADE DE ACEITACAO DA ENTRADA NA FASE NACIONAL POR TER SIDO INTEMPESTIVA. O PRAZO PARA ENTRADA NA FASE NACIONAL EXPIRAVA EM 14.10.2003 ( 20 MESES - BR DESIGNADO APENAS), ELEICAO NAO COMPROVADA, E A PRETENSA ENTRADA NA FASE NACIONAL SO OCORREU EM 16.08.2004. |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |